Liquid Biopsy for Longitudinal Monitoring in Diffuse Midline Glioma (DMG) Patients Protocol/Trial Identifier

Clinical Trial Details

This clinical trial is for participants with newly diagnosed diffuse midline glioma (DMG).

The purpose of this study is to better understand if cerebrospinal fluid (CSF) and blood obtained as a liquid biopsy correlate with disease status in children with diffuse malignant gliomas. This study is being done because CSF and blood can provide critical information about the status of the diffuse midline glioma. Through the CSF and blood samples, researchers can detect molecules called cell free DNA (cfDNA). These molecules can shed off from the tumor and are circulated in the CSF and blood. By analyzing cfDNA, researchers can have a better understanding on the status of the tumor.

This study will include the collection of CSF, blood samples, and implementation of the ventricular access device (VAD) for participants who have not already had a VAD implanted as part of their clinical care.

Participation in this research will last about 2 years including follow-up.

Key Eligibility:

Open to participants with newly diagnosed DMG between 2 and 39 years old who have not received any prior tumor-directed therapy for their DMG.
Newly diagnosed or recurrent DMG patients who are eligible for a VAD or newly diagnosed or recurrent DMG patients with preexisting reservoir or device/shunt or VAD regardless of where they are in the disease continuum.

Detailed eligibility reviewed when participant contacts the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Alexa Kisselbach
212-746-2363
alg9206@med.cornell.edu

Primary Investigator(s)

Mark M Souweidane, MD

Protocol ID(s)

Weill Cornell Medicine IRB #:

2102023267

Status

Open to Enrollment

Age Group

Adult

Disease

Brain Tumor

Glioblastoma